Copenhagen, January 6, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announces that the first subject in the Huadong sponsored phase III clinical study evaluating the efficacy and safety of Wynzora® Cream for the treatment of plaque psoriasis in Chinese patients has successfully been enrolled and dosed. In July 2025, the Phase III clinical trial application filed by Zhongmei Huadong, was approved by the National Medical Products Administration (NMPA) of China.
The completion of the first patient enrollment in the phase III clinical trial of MC2-01 Cream marks a significant milestone in the product’s development process in China and it will further enhance Huadong’s competitiveness in the fields of autoimmune diseases and topical dermatological formulations. Huadong will fully advance the clinical development and registration of the product in China, striving to provide more treatment options for Chinese psoriasis patients.
About Wynzora® Cream
Wynzora® Cream is a cream-based fixed dose combination of calcipotriol and betamethasone dipropionate for topical treatment for plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US 2020, in the European countries 2021, in Australia November 2024 and in Canada November 2025.
About MC2 Therapeutics A/S
MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin through innovative and effective therapies. The company is dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support.
Wynzora® Cream is partnered with leading pharmaceutical companies specializing in dermatology covering more than 40 countries in four continents. The company is based in Hørsholm, Denmark and in Guildford, United Kingdom. For additional information on MC2 Therapeutics, please visit https://www.mc2therapeutics.com
Contact:
Trine Ahlgreen, +45 3150 5036, info@mc2therapeutics.com
About Huadong Medicine
Huadong Medicine Co., Ltd. (SZ.000963) is a leading Chinese pharmaceutical company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales, and marketing capabilities. Huadong Medicine’s product portfolio and pipeline are specialized in oncology, immunology, nephrology, and diabetes. The company has 14,000 employees and one of the most extensive commercial coverage and marketing capabilities in China. ‘Patient Centered, Science Driven’ is Huadong Medicine’s value. For additional information, please visit www.eastchinapharm.com.
Contacts:
Bo Chen, +86 571 8990 3290, ir@eastchinapharm.com
BACK
